7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
Inventors
Stogniew, Martin • Allen, Joshua E.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10953014-B2
Publication Date
2021-03-23
Expiration Date
Abstract
This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
Core Innovation
The invention relates to pharmaceutical composition forms and therapeutic use of compound (1) and pharmaceutically acceptable salts thereof. The disclosed dosage forms include sustained, controlled, delayed, and release concepts, and topical dermatological carrier concepts, with an emphasis on providing therapeutic treatment options for diseases including cancers and other medical conditions.
A central aspect of the invention is treatment of ovarian cancer using compound (1) or a pharmaceutically acceptable salt as salvage therapy, and treatment of ovarian cancer using a therapeutic agent comprising compound (1) or a pharmaceutically acceptable salt within the broader genitourinary cancer context. The document frames therapy lines including first-, second-, third-, salvage, rescue, neoadjuvant, and adjuvant therapy concepts, and further presents a combination-therapy framework for using compound (1) together with second agents, including synergistic combinations.
The invention further describes administration of compound (1), identified as 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, and pharmaceutically acceptable salts thereof in the context of cancer treatment, including oral administration and other routes. The document also includes drug-drug interaction potential, elimination and tonicity concepts, tumor-focused pharmacokinetic and monitoring concepts associated with TRAIL, and nonclinical observations of cell viability, recovery, ER stress response genes, and proteasomal activity.
Claims Coverage
The partial content provides two independent claims. Across these claims, the inventive coverage is focused on administering compound (1) or a pharmaceutically acceptable salt for ovarian cancer, with one claim specifically requiring salvage therapy and the other situating the treatment within genitourinary cancer and identifying ovarian cancer as the indication.
Salvage therapy for ovarian cancer with compound (1)
A method of treatment comprising administering to a subject having ovarian cancer in need of such treatment a pharmaceutically acceptable amount of compound (1) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable amount of compound (1) is administered as a salvage therapy.
Genitourinary cancer treatment where the genitourinary cancer is ovarian cancer using compound (1)
A method of treatment comprising administering to a subject in need of such treatment a therapeutic agent comprising compound (1) or a pharmaceutically acceptable salt thereof, wherein the treatment is for a genitourinary cancer and wherein the genitourinary cancer is ovarian cancer.
Both independent claims cover therapeutic methods for ovarian cancer by administering compound (1) or a pharmaceutically acceptable salt, with one claim limiting the use to salvage therapy and the other defining the cancer category as genitourinary cancer with ovarian cancer as the specific indication.
Stated Advantages
Prognosis improvement/reduced adverse side-effects.
Documented Applications
Salvage therapy for a subject having ovarian cancer using compound (1) or a pharmaceutically acceptable salt thereof.
Treatment for a genitourinary cancer where the genitourinary cancer is ovarian cancer using a therapeutic agent comprising compound (1) or a pharmaceutically acceptable salt thereof.
Interested in licensing this patent?